Engineered deletions of HIV replicate conditionally to reduce disease in nonhuman primates
Fathima N Nagoor Pitchai,Elizabeth J Tanner,Neha Khetan,Gustavo Vasen,Clara Levrel,Arjun J Kumar,Shilpi Pandey,Tracy Ordonez,Philip Barnette,David Spencer,Seung-Yong Jung,Joshua Glazier,Cassandra Thompson,Alicia Harvey-Vera,Hye-In Son,Hye-In Son,Steffanie A Strathdee,Leo Holguin,Ryan Urak,John Burnett,William Burgess,Kathleen Busman-Sahay,Jacob D Estes,Ann Hessell,Christine M Fennessey,Brandon F Keele,Nancy L Haigwood,Leor S Weinberger,Fathima N. Nagoor Pitchai,Elizabeth J. Tanner,Arjun J. Kumar,Steffanie A. Strathdee,Jacob D. Estes,Christine M. Fennessey,Brandon F. Keele,Nancy L. Haigwood,Leor S. Weinberger
DOI: https://doi.org/10.1126/science.adn5866
IF: 56.9
2024-08-09
Science
Abstract:Antiviral therapies with reduced frequencies of administration and high barriers to resistance remain a major goal. For HIV, theories have proposed that viral-deletion variants, which conditionally replicate with a basic reproductive ratio [R 0 ] > 1 (termed "therapeutic interfering particles" or "TIPs"), could parasitize wild-type virus to constitute single-administration, escape-resistant antiviral therapies. We report the engineering of a TIP that, in rhesus macaques, reduces viremia of a highly pathogenic model of HIV by >3log 10 following a single intravenous injection. Animal lifespan was significantly extended, TIPs conditionally replicated and were continually detected for >6 months, and sequencing data showed no evidence of viral escape. A single TIP injection also suppressed virus replication in humanized mice and cells from persons living with HIV. These data provide proof of concept for a potential new class of single-administration antiviral therapies.
multidisciplinary sciences